Featured Press Releases

Xencor Announces Promising Early Results for XmAb942 in First-in-Human Study Targeting IBD

Xencor Announces Promising Early Results for XmAb942 in First-in-Human Study Targeting IBD

Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors

Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors

  • 23 Jul 2024

Cytoki Pharma, ApS (Cytoki), a clinical-stage biotechnology company pioneering a new class of...

ADC Therapeutics shares promising initial LOTIS-7 trial data on ZYNLONTA® combined with a bispecific antibody for relapsed/refractory DLBCL.

ADC Therapeutics shares promising initial LOTIS-7 trial data on ZYNLONTA® combined with a bispecific antibody for relapsed/refractory DLBCL.

Carterra unveils Carterra Ultra™, its most sensitive biosensor platform, advancing fragment and small molecule drug discovery

Carterra unveils Carterra Ultra™, its most sensitive biosensor platform, advancing fragment and small molecule drug discovery

CollPlant Expands Its rhCollagen 3D Bioprinting Portfolio Through the Launch of Ready-to-Print BioFlex

CollPlant Expands Its rhCollagen 3D Bioprinting Portfolio Through the Launch of Ready-to-Print BioFlex

A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

  • Aspera Biomedicines Inc.
  • 18 May 2026
Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio

Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio

  • Galvanize Therapeutics, Inc.
  • 18 May 2026
Peter Menziuso named EVP and President of BD Interventional

Peter Menziuso named EVP and President of BD Interventional

  • BD
  • 18 May 2026
A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

  • Ferring Pharmaceuticals
  • 17 May 2026
Biohack skin longevity with Futurecode Booster

Biohack skin longevity with Futurecode Booster

  • Dermalogica
  • 16 May 2026
ENHERTU received U.S. approval for two new indications in HER2-positive early breast cancer.

ENHERTU received U.S. approval for two new indications in HER2-positive early breast cancer.

  • AstraZeneca
  • 15 May 2026
The Digital Pharma Advances Conference 2026

Most Popular
May   2026
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.